Hado Therapeutics Ltd (UK Reg. 12240559), formerly known as Haiku Therapeutics. We discover pioneering medicines for diseases ranging from rare disorders to indications of significant disease burden. Hado discovered first-in-class compounds for treating Glioblastoma, Parkinson's disease, Diabetic Neuropathy and Bleeding disorders. Our immuno-oncology project aims to develop a first-in-class small molecule that enhances anti-tumour immunity with tumour-destroying ability, thus eliminating tumour burden. This novel and powerful approach counters cancer resistance and is an attractive treatment option for cancer patients who do not respond to existing therapy.